VitalConnect Announces Initiation of TELESTAR-TAVR Clinical Study
Summary
SAN JOSE, Calif.--(BUSINESS WIRE)--VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, announced today that it has begun the TELESTAR-TAVR clinical study (Deployment of Telemedicine for Symptom Tracking And Decrease Readmission Rate in TAVR Patients). The TELESTAR-TAVR Study will evaluate patients who undergo a transcatheter aortic valve replacement (TAVR) and monitor them following the procedure utilizing the latest technology from VitalConnect, VistaSolution LIVE. This information may aid providers to monitor early signs of deterioration, predict possible complications, and adjust treatment strategy to optimize clinical outcomes. Founded in 2011, VitalConnect has deployed more than 100,000 VitalPatches across the world, including care facilities such as Hackensack Medical Center, Northwell Health, and John Radcliffe Hospital-Oxford University. VitalConnect leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms that achieve better health and economic outcomes.
Classifications
AskAI Classifications
LabelsLinked Companies
